Suppr超能文献

人类普伐他汀治疗中断后胆汁脂质输出的变化。

Changes in biliary lipid output after interruption of pravastatin treatment in humans.

作者信息

Hillebrant C G, Eriksson M, Nyberg B, Einarsson K

机构信息

Department of Surgery, Karolinska Institute at Huddinge, University Hospital, Stockholm, Sweden.

出版信息

Eur J Clin Invest. 1996 Dec;26(12):1160-5. doi: 10.1046/j.1365-2362.1996.590608.x.

Abstract

The use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (e.g. pravastatin) has gradually increased in the treatment of hypercholesterolaemia. By inhibiting HMG-CoA reductase (the rate-limiting enzyme in cholesterol synthesis) activity, cholesterol synthesis in the liver is reduced and the plasma level of cholesterol, especially low-density lipoprotein (LDL)-cholesterol, is substantially lowered. Simultaneously, inhibition of HMG CoA reductase activity is associated with increased synthesis and accumulation of larger amounts of HMG CoA reductase enzyme protein. The main purpose of this study was to determine if the cessation of pravastatin treatment causes a rapid increase in the synthesis and biliary secretion of cholesterol, a condition which might lead to a temporarily increased cholesterol saturation of bile. Nine patients undergoing surgery for stones in the common bile duct were fitted with T-tubes in the common bile duct peroperatively; the side arm of the T-tube was left open postoperatively, creating a biliary fistula. All patients were given 6 days' treatment with pravastatin (20 mg b.i.d.) following the operation. Bile was collected from the T-tube, in 12-h fractions during this period and for another 3 days after termination of the treatment. Plasma levels of lipoproteins and lathosterol--reflecting cholesterol synthesis--were determined on several occasions. After cessation of pravastatin treatment, the plasma levels of total cholesterol and LDL-cholesterol increased by 21% and 33% respectively. High-density lipoprotein (HDL)-cholesterol did not change. The plasma level of lathosterol was increased two- to fourfold. Outputs of bile acids and phospholipids were significantly increased (23% and 10% respectively) after termination of treatment, whereas the output of cholesterol was not significantly changed. Cholesterol saturation was reduced by 20%, from 175 +/- 37% to 140 +/- 19%, but this change was not significant. The results indicate that, with the present experimental model (biliary diversion), the synthesis and biliary secretion of bile acids seem to be largely dependent on the de novo synthesis of cholesterol in the liver, whereas the biliary output of cholesterol is not.

摘要

3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(如普伐他汀)在高胆固醇血症治疗中的应用逐渐增多。通过抑制HMG-CoA还原酶(胆固醇合成中的限速酶)的活性,肝脏中的胆固醇合成减少,血浆胆固醇水平,尤其是低密度脂蛋白(LDL)胆固醇水平大幅降低。同时,HMG-CoA还原酶活性的抑制与大量HMG-CoA还原酶蛋白的合成和积累增加有关。本研究的主要目的是确定停用普伐他汀治疗是否会导致胆固醇合成和胆汁分泌迅速增加,这种情况可能会导致胆汁中胆固醇饱和度暂时升高。9例因胆总管结石接受手术的患者在手术中于胆总管置入T形管;术后T形管的侧臂保持开放,形成胆瘘。所有患者术后均接受6天的普伐他汀治疗(20mg,每日2次)。在此期间,每12小时从T形管收集一次胆汁,并在治疗结束后再收集3天。多次测定反映胆固醇合成的血浆脂蛋白和羊毛甾醇水平。停用普伐他汀治疗后,总胆固醇和LDL胆固醇的血浆水平分别升高了21%和33%。高密度脂蛋白(HDL)胆固醇未发生变化。羊毛甾醇的血浆水平增加了2至4倍。治疗结束后,胆汁酸和磷脂的输出量显著增加(分别为23%和10%),而胆固醇的输出量没有显著变化。胆固醇饱和度从175±37%降至140±19%,降低了20%,但这一变化并不显著。结果表明,在目前的实验模型(胆汁引流)中,胆汁酸的合成和胆汁分泌似乎很大程度上依赖于肝脏中胆固醇的从头合成,而胆固醇的胆汁输出则不然。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验